Bo Wang, MD | Medical Oncologist and at WVCI Eugene, Oregon

Bo Wang, MD

Medical Oncologist

Bo Wang, MD | Medical Oncologist and at WVCI Eugene, Oregon

Request an Appointment

Primary Location

Eugene
520 Country Club Road
Eugene, Oregon 97401

Phone: 541-683-5001
Fax: 541-683-1422

Patient Care Philosophy

Dr. Wang was inspired to pursue the study of oncology and blood diseases from an early age due to his experiences of seeing loved ones go through the cancer diagnosis and treatment process. 

“Navigating a cancer diagnosis and therapy can be complex and stressful, but my goal is to simplify the process and make it as smooth as possible for patients and their families.” 

Dr. Wang’s passion for the advancement of cancer research led him to closely work with scientists and other clinicians in the field of immune redirection (taking advantage of patients’ immune systems to fight cancer) and he has published his work in prestigious journals including Nature Medicine, Journal of Hematology Oncology, and Cancer Cell. He is excited to bring cutting-edge, innovative therapies to patients in his community. 

“The science and technology in cancer medicine are advancing at such a rapid speed. I view it as my job to grasp these advancements and mold them to maximally benefit my patients.” 

Personal Information

Dr. Wang grew up an avid skier and fly fisherman in New England. In his free time, he enjoys playing the guitar and staying active with pickup basketball, soccer, and hiking. He also enjoys spending time with his family.

 

Board Certifications

  • Medical Oncology
  • Internal Medicine

Special Interest

Fellowship

Icahn Mount Sinai School of Medicine (Hematology and Medical Oncology)

Residency

Tufts Medical Center

Medical School

Albert Einstein College of Medicine (NY)

Internship

Tufts Medical Center

Additional Information

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. Skoulidis F, ...Wang B, et al. N Engl J Med. 2026 Oct 25. doi: 10.1056/NEJMoa2605703. Online ahead of print.PMID: 42929675

TeLuRide-005: Phase 2 Study of EIK1001 (TLR 7/8 Dual Agonist) Plus Pembrolizumab and Chemotherapy in Patients with Stage IV NSCLC: Results from the Squamous Cohort and Updated Pooled Results. Wang B (First Author), et al. Presented at: European Society for Medical Oncology (ESMO) Congress 2026; October 2026; Poster #2664P.

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC. Garon E, …, Wang B, et al. Future Oncology. 2026; Article ID: IFON 2752788. doi: 10.1080/14796694.2026.2752788

Efficacy, Safety and Cytokine Profiling with Addition of the Toll-Like Receptor (TLR) 7/8 Dual Agonist EIK1001 to Standard of Care First-Line Therapy: The Phase 2 TeLuRide-005 Trial in Stage 4 NSCLC. Wang B, et al. Presented at: ASCO Annual Meeting 2026; Chicago, IL.

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.  Hayashi H, Cho BC,...Wang B, et al. J Thorac Oncol. 2026 Sep;21(9):103894. doi: 10.1016/j.jtho.2026.103894. Epub 2026 Apr 28. 

Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices. Evangelist M, Wang B, Butrynski JE, et.al. JCO Precis Oncol. 2026 Apr;10(4):e2500832. doi: 10.1200/PO-25-00832. Epub 2026 Apr 22.PMID: 42018966

Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists. Banerjee R, Dong S, McCaughan G, Mehra N, Wang B, et. al. Br J Haematol. 2026 May;208(5):1831-1835. doi: 10.1111/bjh.70435. Epub 2026 Mar 17.PMID: 41841734

Testing and treatment patterns in KRAS mutant mNSCLC: Results from the MYLUNG Consortium. Wang B, et al. Journal of Clinical Oncology. 2025.

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. Banerjee R, Wang B, et al. Blood Cancer J. 2023 Nov 6;13(1):162. doi: 10.1038/s41408-023-00937-0.PMID: 37926718

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. Wang B, Ehrlich D, Lu W, Dowling P, Yuan RR. Journal of Hematology & Oncology. 2014;7:91.

What Satisfied Patients Are Saying About Dr. Wang